Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1–2 dose-confirmation studyKristina M. Brooks, Patricia M. Flynn, S. M. Ward et al.|The Lancet HIV|2023Cited by 13
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014Ann J. Melvin, Ka Lai Yee, Kathryn P. Gray et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2022Cited by 3
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 ResultsDwight E. Yin, S. M. Ward, Yasha Rani et al.|The Pediatric Infectious Disease Journal|2025Cited by 1